A pharma merger's impact ripples across West Virginia as Viatris plant closes

For more than 11 years, Albert Haught has pulled up to an unassuming building on Chestnut Ridge Road in Morgantown, West Virginia every weekday morning. This past Tuesday was the last time he entered.

Haught is one of over 1,400 employees who will lose his job on Saturday when the factory, a hub for generic drug manufacturing for more than five decades, shuts its doors. The plant is one of up to 15 being shuttered, downsized or sold amid a restructuring of Viatris, the company formed when Mylan and Pfizer's Upjohn unit merged in 2019.